Norlux Neuro-Oncology Laboratory
Headed by Dr. Simone P. Niclou, the NorLux Neuro-Oncology Laboratory has developed a strong translational research programme on brain cancers to understand the underlying biological mechanisms of malignant gliomas and develop innovative treatment strategies based on clinically relevant animal models. The research focuses on tumor angiogenesis, metabolism, tumour heterogeneity and treatment resistance and applies emerging molecular and cellular approaches, including large scale screens, genomics, proteomics, patient derived animal models and in vivo imaging (MRI & PET). Niclou is also adjunct professor at the Kristian Gerhard Jebsen Brain Tumour Research Centre of the University of Bergen (Norway), with which she has a longstanding scientific partnership.
The laboratory is organized in the following sub-groups:
Translational aspects of brain tumour research, with a focus on tumour angiogenesis, invasion and tumour metabolism.
Beyond their role in preventing genetic instability and tumorigenesis, DNA repair and epigenetic mechanisms also contribute to the resistance of cancer cells to chemotherapeutic genotoxics, and are responsible in great part for the failure of current anti-GBM therapies. Our objectives are to better understand the mechanisms that operate to repair DNA damage induced by chemoradiation in GBMs, and identify critical targets and novel strategies to prevent chemoresistance and tumor relapse.
The Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) is a strategic alliance between LIH and the German Cancer Research Centre (DKFZ) established in 2016 to advance research on oncolytic virus immunotherapy.